Heidelberg Pharma AG

Regulatory Filings • Jun 30, 2014

News Details

Ad-hoc | 30 June 2014 08:16

WILEX AG: WILEX and RedHill Biopharma enter into an exclusive license agreement for MESUPRON(R)

WILEX AG / Key word(s): Alliance

30.06.2014 08:16

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX and RedHill Biopharma enter into an exclusive license agreement for
MESUPRON(R)

Munich, Germany, 30 June 2014. WILEX AG (ISIN DE0006614720/ WL6 / FSE) and
RedHill Biopharma Ltd. (NASDAQ: RDHL; TASE: RDHL), an Israeli
biopharmaceutical company focused on late clinical-stage drugs for
inflammatory and gastrointestinal diseases, including cancer, today
announced that they have signed an exclusive license agreement for the
oncology drug candidate MESUPRON(R). The small molecule is a proprietary,
first-in-class urokinase-type plasminogen activator (uPA) inhibitor
administered by oral capsule. WILEX has completed several clinical studies
with MESUPRON(R) in different indications, including two Phase II proof of
concept studies for pancreatic cancer and metastatic breast cancer.

Under the terms of the agreement, RedHill acquired the exclusive
development and commercialization rights to MESUPRON(R) outside China, Hong
Kong, Taiwan and Macao for all indications. RedHill will pay WILEX an
upfront payment of USD 1 million and potential tiered royalties on net
revenues, ranging from mid-teens up to 30%. RedHill will be responsible for
development, regulatory and commercialization of MESUPRON(R).

---

Information and Explaination of the Issuer to this News:

About MESUPRON(R)
MESUPRON(R) (INN: Upamostat) is a proprietary, first-in-class
urokinase-type plasminogen activator (uPA) inhibitor administered by oral
capsule. The uPA system has been shown to play a key role in tumor cell
growth, invasion and the metastasis process. High uPA levels are associated
with poor prognosis in various solid tumor cancers, such as pancreatic,
gastric, breast and prostate cancers. MESUPRON(R) presents a promising new
non-cytotoxic approach to cancer therapy with several potential mechanisms
of action to inhibit both tumor metastasis and growth. MESUPRON(R) has
completed several Phase I studies and two Phase II proof of concept
studies, the first Phase II study in locally advanced non-metastatic
pancreatic cancer and the second in metastatic breast cancer, which have
established its safety and tolerability profile. The Phase II studies with
MESUPRON(R) in both indications suggested activity as measured by both
tumor response rate and overall survival of patients when administered in
combination with first-line chemotherapeutic agents.

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company's portfolio includes diagnostic and therapeutic
product candidates for the specific detection and targeted treatment of
various types of cancer based on antibodies and small molecules. The WILEX
subsidiary Heidelberg Pharma GmbH in Ladenburg, Germany, offers preclinical
contract research services and an antibody drug conjugate (ADC) technology
platform. WILEX AG is listed at the Frankfurt Stock Exchange: ISIN
DE0006614720 / WKN 661472 / Symbol WL6. More information is available at
www.wilex.com.

Company contact IR/PR support
WILEX AG MC Services AG
Sylvia Wimmer Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-29 Executive Director
Email: investors[at]wilex.com Tel.: +49-89-210 228-40
Grillparzerstr. 10, 81675 Munich, Email: katja.arnold[at]mc-
Germany services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

30.06.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---